D-CYCLOSERINE TREATMENT OF ALZHEIMER-DISEASE

被引：46

作者：

RANDOLPH, C ^{[1
]}

ROBERTS, JW ^{[1
]}

TIERNEY, MC ^{[1
]}

BRAVI, D ^{[1
]}

MOURADIAN, MM ^{[1
]}

CHASE, TN ^{[1
]}

机构：

[1] NINCDS,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892

来源：

ALZHEIMER DISEASE & ASSOCIATED DISORDERS | 1994年 / 8卷 / 03期

关键词：

ALZHEIMER DISEASE; N-METHYL-D-ASPARTATE; GLURAMATE; CYCLOSERINE;

D O I：

10.1097/00002093-199408030-00006

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1 glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 +/- 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a ''best dose'' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.

引用

页码：198 / 205

页数：8

共 41 条

[1] COMPETITIVE AND NONCOMPETITIVE NMDA RECEPTOR ANTAGONISTS IN SPATIAL-LEARNING TASKS [J].